Abstract：
Two recent studies, by Casirati et al. and Wellhausen et al., report genetically engineering normal hematopoietic stem and progenitor cells (HSPCs) to be resistant to chimeric antigen receptor (CAR)-T cells, by changing a single amino acid in the target protein that abrogates CAR binding, without compromising protein function. This allows for selective targeting of cancer cells without harming normal hematopoietic cells.
摘要：
最近的两项研究，由Casirati等人。和Wellhausen等人。,报告基因工程正常造血干细胞和祖细胞（HSPCs）对嵌合抗原受体（CAR）-T细胞具有抗性，通过改变靶蛋白中消除CAR结合的单个氨基酸，不损害蛋白质功能。这允许选择性靶向癌细胞而不损害正常造血细胞。
